Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

publication venue for

Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers. 2019
Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non-small-cell Lung Cancer Exhibiting Resistance to Ceritinib. 2015
Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib. 2014
Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. 2013
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. 2011
Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. 2010
Clinical significance of a prospective large genomic screening for small-cell lung cancer: the genetic classification and a biomarker driven phase II trial of gedatolisib. 2024
Prevalence and Therapeutic Targeting of High Level ERBB2 Amplification in Non-Small Cell Lung Cancer. 2024
Microsatellite instability and mismatch repair deficiency define a distinct subset of lung cancers characterized by smoking exposure, high tumor mutational burden and recurrent somatic MLH1 inactivation. 2023
Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF Non-V600E Mutations: A Multi-Institutional Genomic Screening Study (LC-SCRUM-Asia).. 18. 2023
International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy. 2023
Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation.. 18. 2023
Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.. 18. 2023
Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers.. 18. 2022
Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228.. 18. 2022
A Knock-in Mouse Model of Thymoma with the GTF2I L424H Mutation. 2022
Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy. 2022
POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC.. 17. 2022
Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC.. 17. 2022
Tumor and Tumor-Associated Macrophage Programmed Death-Ligand 1 Expression Is Associated With Adjuvant Chemotherapy Benefit in Lung Adenocarcinoma.. 17. 2021
Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events.. 16. 2021
Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC. 2021
Invasive Mucinous Adenocarcinomas With Spatially Separate Lung Lesions: Analysis of Clonal Relationship by Comparative Molecular Profiling.. 16. 2021
The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC.. 16. 2021
Durable Response in Patients With Thymic Carcinoma Treated With Pembrolizumab After Prolonged Follow-Up.. 16. 2020
SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization.. 15. 2020
Inherited Rare, Deleterious Variants in ATM Increase Lung Adenocarcinoma Risk.. 15. 2020
The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma.. 15. 2020
Multi-Institutional Prospective Validation of Prognostic mRNA Signatures in Early Stage Squamous Lung Cancer (Alliance).. 15. 2020
Role of mTOR As an Essential Kinase in SCLC.. 15. 2020
A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee.. 15. 2020
Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center.. 15. 2020
Tumor Spread Through Air Spaces Is a Predictor of Occult Lymph Node Metastasis in Clinical Stage IA Lung Adenocarcinoma.. 15. 2020
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.. 15. 2020
Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas.. 15. 2019
Three-Dimensional Histologic, Immunohistochemical, and Multiplex Immunofluorescence Analyses of Dynamic Vessel Co-Option of Spread Through Air Spaces in Lung Adenocarcinoma.. 15. 2019
The International Association for the Study of Lung Cancer Thymic Tumors Staging Project: The Impact of the Eighth Edition of the Union for International Cancer Control and American Joint Committee on Cancer TNM Stage Classification of Thymic Tumors.. 15. 2019
SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas.. 15. 2019
The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non-Small Cell Lung Cancer.. 15. 2019
EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach.. 15. 2019
Expansion of the Concept of Micropapillary Adenocarcinoma to Include a Newly Recognized Filigree Pattern as Well as the Classical Pattern Based on 1468 Stage I Lung Adenocarcinomas.. 14. 2019
Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations.. 14. 2019
Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer.. 14. 2019
MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.. 14. 2019
Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.. 14. 2019
Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.. 14. 2019
Spread Through Air Spaces (STAS) Is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung.. 14. 2019
Checkpoint Kinase 1 Inhibition Enhances Cisplatin Cytotoxicity and Overcomes Cisplatin Resistance in SCLC by Promoting Mitotic Cell Death.. 14. 2019
The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.. 14. 2019
Surgical Resection of SCLC: Prognostic Factors and the Tumor Microenvironment.. 14. 2019
Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis.. 14. 2018
Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.. 14. 2018
Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements.. 14. 2018
Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma.. 14. 2018
FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC.. 13. 2018
Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma.. 14. 2018
Procedure-Specific Risk Prediction for Recurrence in Patients Undergoing Lobectomy or Sublobar Resection for Small (≤2 cm) Lung Adenocarcinoma: An International Cohort Analysis.. 14. 2018
Lobectomy Is Associated with Better Outcomes than Sublobar Resection in Spread through Air Spaces (STAS)-Positive T1 Lung Adenocarcinoma: A Propensity Score-Matched Analysis.. 14. 2018
Implications of the Eighth Edition of the TNM Proposal: Invasive Versus Total Tumor Size for the T Descriptor in Pathologic Stage I-IIA Lung Adenocarcinoma.. 13. 2018
Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.. 13. 2018
Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.. 13. 2018
New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.. 13. 2018
PD-L1 Expression Heterogeneity in Non-Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections.. 13. 2018
The IASLC Lung Cancer Staging Project: A Renewed Call to Participation.. 13. 2018
Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung.. 13. 2017
BRMS1 Expression in Surgically Resected Lung Adenocarcinoma Predicts Future Metastases and Is Associated with a Poor Prognosis.. 13. 2017
Combined Small Cell Carcinoma of the Lung: Is It a Single Entity?. 13. 2017
The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer.. 12. 2017
The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases.. 12. 2016
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non-Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database.. 12. 2016
Spread through Air Spaces (STAS) Is an Independent Predictor of Recurrence and Lung Cancer-Specific Death in Squamous Cell Carcinoma.. 12. 2016
The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma.. 11. 2016
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma.. 11. 2016
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma.. 11. 2016
Anatomical Segmentectomy and Wedge Resections Are Associated with Comparable Outcomes for Patients with Small cT1N0 Non-Small Cell Lung Cancer.. 11. 2016
Patients with a Previous History of Malignancy Undergoing Lung Cancer Screening: Clinical Characteristics and Radiologic Findings.. 11. 2016
North American Multicenter Volumetric CT Study for Clinical Staging of Malignant Pleural Mesothelioma: Feasibility and Logistics of Setting Up a Quantitative Imaging Study.. 11. 2016
PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors.. 11. 2016
Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas.. 11. 2016
The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Application of TNM Staging Rules to Lung Cancer Presenting as Multiple Nodules with Ground Glass or Lepidic Features or a Pneumonic Type of Involvement in the Forthcoming Eighth Edition of the TNM Classification.. 11. 2016
The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer.. 11. 2016
The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification.. 11. 2016
The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer.. 11. 2016
Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study.. 11. 2016
KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.. 11. 2016
Are Anthracycline-Based Regimens Truly Indicated To Be the Standard Chemotherapy Regimen for Thymic Carcinoma?. 11. 2016
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.. 11. 2016
Adaptive Neoadjuvant Chemotherapy Guided by (18)F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN Trial.. 11. 2015
Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma.. 11. 2015
Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas.. 10. 2015
Impact of an Interactive On-line Tool on Therapeutic Decision-Making for Patients with Advanced Non-Small-Cell Lung Cancer.. 10. 2015
Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma: Tumor-Infiltrating CD10+ Neutrophil/CD20+ Lymphocyte Ratio as an Independent Prognostic Factor.. 10. 2015
A Predictive Model for Lymph Node Involvement with Malignancy on PET/CT in Non-Small-Cell Lung Cancer.. 10. 2015
The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer.. 10. 2015
Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.. 10. 2015
Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for Small Stage I Lung Adenocarcinomas.. 10. 2015
Cost-effectiveness of multiplexed predictive biomarker screening in non-small-cell lung cancer.. 10. 2015
The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung.. 10. 2015
Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas.. 10. 2015
Massively parallel sequencing identifies recurrent mutations in TP53 in thymic carcinoma associated with poor prognosis.. 10. 2015
Cognitive and brain structural changes in a lung cancer population.. 10. 2015
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.. 10. 2015
Clinical characteristics and outcomes for patients with thymic carcinoma: evaluation of Masaoka staging.. 9. 2014
Clinical characteristics and course of 63 patients with BRAF mutant lung cancers.. 9. 2014
Development of the international thymic malignancy interest group international database: an unprecedented resource for the study of a rare group of tumors.. 9. 2014
A prospective study of tumor suppressor gene methylation as a prognostic biomarker in surgically resected stage I to IIIA non-small-cell lung cancers.. 9. 2014
Reproducibility of histopathological diagnosis in poorly differentiated NSCLC: an international multiobserver study.. 9. 2014
The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors.. 9. 2014
The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the N and M components for the forthcoming (8th) edition of the TNM classification of malignant tumors.. 9. 2014
The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the T Component for the forthcoming (8th) edition of the TNM classification of malignant tumors.. 9. 2014
The ITMIG/IASLC Thymic Epithelial Tumors Staging Project: A Proposed Lymph Node Map for Thymic Epithelial Tumors in the Forthcoming 8th Edition of the TNM Classification of Malignant Tumors.. 9. 2014
Comprehensive pathological analyses in lung squamous cell carcinoma: single cell invasion, nuclear diameter, and tumor budding are independent prognostic factors for worse outcomes.. 9. 2014
A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer.. 9. 2014
Preoperative computed tomography findings predict surgical resectability of thymoma.. 9. 2014
Small-cell lung cancers in patients who never smoked cigarettes.. 9. 2014
Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee.. 9. 2014
ALK/EML4 fusion gene may be found in pure squamous carcinoma of the lung.. 9. 2014
Outcomes of unresected ground-glass nodules with cytology suspicious for adenocarcinoma.. 9. 2014
Characterization of fibroblast growth factor receptor 1 in small-cell lung cancer.. 9. 2014
Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations.. 9. 2014
Thymic carcinoma: a cohort study of patients from the European society of thoracic surgeons database.. 9. 2014
Failure patterns relative to radiation treatment fields for stage II-IV thymoma.. 9. 2014
Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report.. 9. 2014
Esophageal cancer recurrence patterns and implications for surveillance.. 8. 2013
Prognostic validation of the body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index in inoperable non-small-cell lung cancer.. 8. 2013
The IASLC/ITMIG thymic malignancies staging project: development of a stage classification for thymic malignancies.. 8. 2013
Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.. 8. 2013
Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung.. 8. 2013
A prediction model for pathologic N2 disease in lung cancer patients with a negative mediastinum by positron emission tomography.. 8. 2013
Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers.. 8. 2013
Distinguishing benign thymic lesions from early-stage thymic malignancies on computed tomography.. 8. 2013
Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer.. 8. 2013
Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.. 8. 2013
Characterization and management of cardiac involvement of thymic epithelial tumors.. 8. 2013
Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.. 8. 2013
Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers.. 8. 2013
Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.. 8. 2013
Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.. 7. 2012
The introduction of systematic genomic testing for patients with non-small-cell lung cancer.. 7. 2012
Initial analysis of the international association for the study of lung cancer mesothelioma database.. 7. 2012
Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.. 7. 2012
Clinical outcomes with perioperative chemotherapy in sarcomatoid carcinomas of the lung.. 7. 2012
High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology.. 7. 2012
Screening for germline EGFR T790M mutations through lung cancer genotyping.. 7. 2012
NUT rearrangement is uncommon in human thymic epithelial tumors.. 7. 2012
EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib.. 7. 2012
Poly adenosine diphosphate-ribose polymerase inhibitors and heat shock protein 90 inhibitors.. 6. 2011
Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial.. 6. 2011
Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens.. 6. 2011
A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer.. 6. 2011
Contemporary results of surgical resection of non-small cell lung cancer after induction therapy: a review of 549 consecutive cases.. 6. 2011
A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.. 6. 2011
Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group.. 6. 2011
Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer.. 6. 2011
Chemotherapy definitions and policies for thymic malignancies.. 6. 2011
Resection of primary mediastinal non-seminomatous germ cell tumors: a 28-year experience at memorial sloan-kettering cancer center.. 6. 2011
Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.. 6. 2011
Preoperative taxane-based chemotherapy and celecoxib for carcinoma of the esophagus and gastroesophageal junction: results of a phase 2 trial.. 6. 2011
Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.. 6. 2011
Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma.. 6. 2011
Palliation and pleurodesis in malignant pleural effusion: the role for tunneled pleural catheters.. 6. 2011
Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations.. 6. 2011
Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing.. 6. 2011
Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans.. 6. 2011
Epithelial tumors of the thymic gland are rare malignancies. Foreword.. 5. 2010
Frequency of use and predictors of cancer-directed surgery in the management of malignant pleural mesothelioma in a community-based (Surveillance, Epidemiology, and End Results [SEER]) population.. 5. 2010
Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer.. 5. 2010
Expression and mutational status of c-kit in thymic epithelial tumors.. 5. 2010
Insulin-like growth factor-1 receptor expression in thymic malignancies.. 5. 2010
Current dyspnea among long-term survivors of early-stage non-small cell lung cancer.. 5. 2010
Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.. 5. 2010
Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scans.. 5. 2010
Epidermal growth factor receptor, C-kit, and Her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Oncology Group study.. 5. 2010
Are there imaging characteristics associated with epidermal growth factor receptor and KRAS mutations in patients with adenocarcinoma of the lung with bronchioloalveolar features?. 5. 2010
Predictors of outcomes after surgical treatment of synchronous primary lung cancers.. 5. 2010
Phase I trial of intrapleural docetaxel administered through an implantable catheter in subjects with a malignant pleural effusion.. 5. 2010
Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas.. 4. 2009
Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma.. 4. 2009
Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer.. 4. 2009
Patterns of local and nodal failure in malignant pleural mesothelioma after extrapleural pneumonectomy and photon-electron radiotherapy.. 4. 2009
The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer.. 4. 2009
The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer.. 3. 2008
Promising survival in patients with recurrent non-small cell lung cancer treated with docetaxel and gemcitabine in combination as second-line therapy.. 3. 2008
Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma.. 3. 2008
Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.. 3. 2008
Prognostic factors after combined modality treatment of squamous cell carcinoma of the esophagus.. 2. 2007
A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500).. 2. 2007
Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center.. 2. 2007
Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels.. 2. 2007
The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.. 2. 2007
A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer.. 2. 2007
The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer.. 2. 2007
The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer.. 2. 2007
Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma.. 2. 2007
Phase I study of radical thoracic radiation, weekly irinotecan, and cisplatin in locally advanced non-small cell lung carcinoma.. 2. 2007
Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial.. 1. 2006
Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer.. 1. 2006
The "Radical" Palliation That Increases Survival in Malignant Pleural Mesothelioma.. 14. 2019
Author's Reply.. 14. 2019
Disease Response with the Addition of Platinum-Based Chemotherapy to Pembrolizumab after Progression on Pembrolizumab Monotherapy in PD-L1-Expressing Non-Small Cell Lung Cancer.. 13. 2018
Systemic inflammation, cardiorespiratory fitness, and quality of life in patients with advanced non-small cell lung cancer.. 3. 2008
Reply to Dr. Goto's Letter: "A Thymoma Mouse Model Harboring a Gtf2i L424H Mutation". 2022
Pathologic Assessment of Lung Squamous Cell Carcinoma After Neoadjuvant Immunotherapy. 2021
Spread Through Air Spaces Is Prognostic in Neuroendocrine Lung Tumors and Can Be Distinguished From Artifacts. 2020
The Newly Described Filigree Pattern Is an Expansion of the Micropapillary Adenocarcinoma Concept Rather Than a Proposed New Subtype. 2020
Multiple Abdominal Port Site Recurrences after Esophagectomy for Low-Stage Adenocarcinoma. 2017
Testing for Neuroendocrine Immunohistochemical Markers Should Not Be Performed in Poorly Differentiated NSCCs in the Absence of Neuroendocrine Morphologic Features according to the 2015 WHO Classification. 2016
International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 report. 2012
Cancer stem cells. 2009
Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. 2006
Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma. 2006
The International Association for the Study of Lung Cancer Molecular Database Project: Objectives, Challenges, and Opportunities.. 16. 2021
The Evolving Landscape of Resistance to Osimertinib.. 15. 2020
Analyzing the Thin Tail: Searching for Biomarkers of Exceptional Survival in SCLC.. 14. 2019
Large No More: The Journey of Pulmonary Large Cell Carcinoma from Common to Rare Entity.. 14. 2019
What Can We Learn From the French Experience in Systemic Treatment of Thymic Epithelial Tumors?. 13. 2018
Histone Code Aberrancies in Small Cell Lung Cancer.. 12. 2017
Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart.. 10. 2015
RET mutations in neuroendocrine tumors: including small-cell lung cancer.. 9. 2014
Thymomas: the need for prospective studies.. 8. 2013
Pem and the cost of multicycle maintenance.. 5. 2010
Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift.. 5. 2010
International thymic malignancy interest group.. 5. 2010
The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. 2020
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. 2019
A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Taskforce. 2019
Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. 2018
Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies. 2017
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? 2016
Clinician Perspectives on Current Issues in Lung Cancer Drug Development. 2016
The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. 2016
Scientific Advances in Lung Cancer 2015. 2016
The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification. 2016
Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? 2016
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer. 2015
Forty years of the international association for study of lung cancer pathology committee. 2014
Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions. 2014
Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice. 2014
Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC. 2014
Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials. 2010
Tobacco Smoking and Risk of Second Primary Lung Cancer. 2021
New Approaches to SCLC Therapy: From the Laboratory to the Clinic. 2020
IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. 2020
Scientific Advances in Thoracic Oncology 2016. 2017
Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: a time for excitement and equipoise. 2008

VIVO Weill Cornell Medical College

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

Electronic International Standard Serial Number (EISSN)